Value Investor
Start free

Oncolytics Biotech

ONCY on Nasdaq. Market value $77m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

What to watch out for

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 75 funds in all.

Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

1 investor owns more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 10 insiders bought $363,232 of shares on the open market.

  • Kelly Jared
    Chief Executive Officer, Director
    Bought
    Date
    12 March 2026
    Shares
    5,050
    Price
    $0.96
    Value
    $4,848
  • Parsons James T.
    Director
    Bought
    Date
    11 March 2026
    Shares
    10,000
    Price
    $1.03
    Value
    $10,300
  • Seizinger Bernd R.
    Director
    Bought
    Date
    12 February 2026
    Shares
    40,000
    Price
    $0.85
    Value
    $34,000
  • Pisano Wayne
    Director
    Bought
    Date
    12 February 2026
    Shares
    30,000
    Price
    $0.84
    Value
    $25,200
  • Look Kirk
    Chief Financial Officer
    Bought
    Date
    12 February 2026
    Shares
    12,000
    Price
    $0.84
    Value
    $10,080
  • Kelly Jared
    Chief Executive Officer, Director
    Bought
    Date
    12 February 2026
    Shares
    29,500
    Price
    $0.84
    Value
    $24,780
  • Heineman Thomas Charles
    Chief Medical Officer
    Bought
    Date
    12 February 2026
    Shares
    12,132
    Price
    $0.83
    Value
    $10,070
  • Hagerman Allison
    VP, Product Development
    Bought
    Date
    12 February 2026
    Shares
    10,000
    Price
    $0.83
    Value
    $8,300
  • Brown Deborah Margaret
    Director
    Bought
    Date
    12 February 2026
    Shares
    25,000
    Price
    $0.85
    Value
    $21,250
  • Andrews Patricia S
    Director
    Bought
    Date
    12 February 2026
    Shares
    35,400
    Price
    $0.86
    Value
    $30,444

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Oncolytics Biotech’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 12 Aug 2026 and 17 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “These conditions raise substantial doubt about our ability to continue as a going concern.”
    Show the full paragraph
    As of June 30, 2026, we had cash and cash equivalents of $ 4,115 . Based on our current operating plan, we expect that our existing cash resources, even when considered together with capital that may be raised under our equity distribution arrangements, are sufficient to fund near‑term operating milestones but are not sufficient to fund our planned operations for at least twelve months from the date of issuance of our condensed consolidated financial statements included in this quarterly report. These conditions raise substantial doubt about our ability to continue as a going concern.

    From the 10-Q filed 12 August 2026, Part I, Item 1. Financial Statements. Read it in the filing

  • Changed auditor

    Worth knowing

    The company changed its auditor (the firm that checks its books) in the last two years.

    “On July 6, 2026, due to the Company’s corporate restructuring, the Audit Committee of the Board of Directors of Oncolytics Biotech Inc. (the “ Company ”), unanimously voted to disengage Ernst & Young LLP (“ EY ”) as the Company’s independent registered public accounting firm”

    From an 8-K filed 8 July 2026: Change of auditor. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.